<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-5082-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MYGAL 20 mg Film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TADALAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TABUK PHARMACEUTICAL MANUFACTURING CO." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TABUK PHARMACEUTICAL MANUFACTURING CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CIGALAH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Mygal contains the active substance tadalafil which belongs to a<br />group of medicines called phosphodiesterase type 5 inhibitors.<br />Mygal is used to treat adult men with:<br />Erectile dysfunction. This is when a man cannot get, or keep a<br />hard, erect penis suitable for sexual activity. Mygal has been<br />shown to significantly improve the ability of obtaining a hard erect<br />penis suitable for sexual activity. Following sexual stimulation<br />Mygal works by helping the blood vessels in your penis to relax,<br />allowing the flow of blood into your penis. The result of this is<br />improved erectile function. Mygal will not help you if you do not<br />have erectile dysfunction. It is important to note that Mygal for<br />the treatment of erectile dysfunction does not work if there is no<br />sexual stimulation. You and your partner will need to engage in<br />foreplay, just as you would if you were not taking a medicine for<br />erectile dysfunction.<br />Mygal 5 mg is used to treat adult men with:<br />Urinary symptoms associated with a common condition called<br />benign prostatic hyperplasia. This is when the prostate gland<br />gets bigger with age. Symptoms include difficulty in starting to<br />pass water, a feeling of not completely emptying the bladder and a<br />more frequent need to pass water even at night. Mygal improves<br />blood flow to, and relaxes the muscles of, the prostate and bladder<br />which may reduce symptoms of benign prostatic hyperplasia.<br />Mygal has been shown to improve these urinary symptoms as<br />early as 1-2 weeks after starting treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Do not take Mygal<br />- If you are allergic to tadalafil or any of the other ingredients of<br />this medicine.<br />- If you are taking any form of organic nitrate or nitric oxide<br />donors such as amyl nitrite. This is a group of medicines<br />(&ldquo;nitrates&rdquo;) used in the treatment of angina pectoris (&ldquo;chest<br />pain&rdquo;). Mygal has been shown to increase the effects of these<br />medicines. If you are taking any form of nitrate or are unsure tell<br />your doctor.<br />- If you have serious heart disease or recently had a heart attack<br />within the last 90 days.<br />- If you recently had a stroke within the last 6 months.<br />- If you have low blood pressure or uncontrolled high blood<br />pressure.<br />- If you ever had loss of vision because of non-arteritic anterior<br />ischemic optic neuropathy (NAION), a condition described as<br />&ldquo;stroke of the eye&rdquo;.<br />Warnings and precautions<br />Talk to your doctor before taking Mygal.<br />Be aware that sexual activity carries a possible risk to patients<br />with heart disease because it puts an extra strain on your heart. If<br />you have a heart problem you should tell your doctor.<br />Since benign prostatic hyperplasia and prostate cancer may have<br />the same symptoms, your doctor will check you for prostate<br />cancer before starting treatment with Mygal for benign prostatic<br />hyperplasia. Mygal does not treat prostate cancer.<br />Before taking the tablets, tell your doctor if you have:<br />- Sickle cell anemia (an abnormality of red blood cells).<br />- Multiple myeloma (cancer of the bone marrow).<br />- Leukemia (cancer of the blood cells).<br />- Any deformation of your penis.<br />- A serious liver problem.<br />- A severe kidney problem.<br />It is not known if Mygal is effective in patients who have had:<br />- Pelvic surgery.<br />- Removal of all or part of the prostate gland in which nerves of<br />the prostate are cut (radical non-nerve-sparing prostatectomy).<br />If you experience sudden decrease or loss of vision, stop taking<br />Mygal and contact your doctor immediately.<br />Mygal is not intended for use by women.<br />Children and adolescents<br />Mygal is not intended for use by children and adolescents under<br />the age of 18.<br />Other medicines and Mygal<br />Tell your doctor if you are taking, have recently taken or might<br />take any other medicines.<br />Do not take Mygal if you are already taking nitrates.<br />Some medicines may be affected by Mygal or they may affect<br />how well Mygal will work. Tell your doctor or pharmacist if you<br />are already taking:<br />- An alpha blocker (used to treat high blood pressure or urinary<br />symptoms associated with benign prostatic hyperplasia).<br />- Other medicines to treat high blood pressure.<br />- A 5- alpha reductase inhibitor (used to treat benign prostatic<br />hyperplasia).<br />- Medicines such as ketoconazole tablets (to treat fungal<br />infections) and protease inhibitors for treatment of AIDS or HIV<br />infection.<br />- Phenobarbital, phenytoin and carbamazepine (anticonvulsant<br />medicines).<br />- Rifampicin, erythromycin , clarithromycin or itraconazole.<br />- Other treatments for erectile dysfunction.<br />Mygal with drink and alcohol<br />Information on the effect of alcohol is in section 3. Grapefruit<br />juice may affect how well Mygal will work and should be taken<br />with caution. Talk to your doctor for further information.<br />Fertility<br />When dogs were treated there was reduced sperm development in<br />the testes. A reduction in sperm was seen in some men. These<br />effects are unlikely to lead to a lack of fertility.<br />Driving and using machines<br />Some men taking Mygal in clinical studies have reported<br />dizziness. Check carefully how you react to the tablets before<br />driving or using machines.<br />Mygal contains lactose:<br />If you have an intolerance to some sugars, contact your doctor<br />before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Always take this medicine exactly as your doctor has told you.<br />Check with your doctor or pharmacist if you are not sure.<br />Mygal tablets are for oral use in men only. Swallow the tablet<br />whole with some water. The tablets can be taken with or without<br />food.<br />For the treatment of erectile dysfunction<br />The recommended starting dose is 5 mg or 10 mg taken once a<br />day at approximately the same time of the day. Your doctor may<br />lower or raise your dose, depending on how your body reacts to<br />Mygal and your health condition.<br />Do not take Mygal more than once a day.<br />When taken once a day Mygal allows you to obtain an erection,<br />when sexually stimulated, at any time point during the 24 hours of<br />the day. Once a day dosing of Mygal may be useful to men who<br />anticipate having sexual activity two or more times per week.<br />It is important to note that Mygal does not work if there is no<br />sexual stimulation. You and your partner will need to engage in<br />foreplay, just as you would if you were not taking a medicine for<br />erectile dysfunction.<br />For the treatment of benign prostatic hyperplasia<br />The dose is one 5 mg tablet taken once a day at approximately the<br />same time of the day. If you have benign prostatic hyperplasia and<br />erectile dysfunction, the dose remains one 5 mg tablet taken once<br />a day.<br />Do not take Mygal more than once a day.<br />Drinking alcohol may affect your ability to get an erection and<br />may temporarily lower your blood pressure. If you have taken or<br />are planning to take Mygal, avoid excessive drinking (blood<br />alcohol level of 0.08% or greater), since this may increase the risk<br />of dizziness when standing up.<br />If you take more Mygal than you should<br />Contact your doctor. You may experience side effects described in<br />section 4.<br />If you forget to take Mygal<br />Take your dose as soon as you remember but do not take a double<br />dose to make up for a forgotten tablet. You should not take Mygal<br />more than once a day.<br />If you have any further questions on the use of this medicine, ask<br />your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Like all medicines, this medicine can cause side effects, although<br />not everybody gets them. These effects are normally mild to<br />moderate in nature.<br />If you experience any of the following side effects stop using<br />the medicine and seek medical help immediately:<br />- Allergic reactions including rashes (frequency uncommon).<br />- Chest pains - do not use nitrates but seek immediate medical<br />assistance (frequency uncommon).<br />- Prolonged and possibly painful erection after taking Mygal<br />(frequency rare). If you have such an erection, which lasts<br />continuously for more than 4 hours you should contact a doctor<br />immediately.<br />- Sudden loss of vision (frequency rare).<br />Other side effects have been reported:<br />Common (seen in 1 to 10 in every 100 patients)<br />- Headache, back pain, muscle aches, pain in arms and legs, facial<br />flushing, nasal congestion, indigestion and reflux.<br />Uncommon (seen in 1 to 10 in every 1,000 patients)<br />- Dizziness, stomach ache, blurred vision, eye pain, increased<br />sweating, difficulty in breathing, penile bleeding, presence of<br />blood in semen and/or urine, pounding heartbeat sensation, a fast<br />heart rate, high blood pressure, low blood pressure, nose bleeds<br />and ringing in the ears.<br />Rare (seen in 1 to 10 in every 10,000 patients)<br />- Fainting, seizures and passing memory loss, swelling of the<br />eyelids, red eyes, sudden decrease or loss of hearing and hives<br />(itchy red welts on the surface of the skin).<br />- Heart attack and stroke have also been reported rarely in men<br />taking Mygal. Most of these men had known heart problems<br />before taking this medicine.<br />- Partial, temporary, or permanent decrease or loss of vision in<br />one or both eyes has been rarely reported.<br />Some additional rare side effects have been reported in men<br />taking Mygal that were not seen in clinical trials. These include:<br />- Migraine, swelling of the face, serious allergic reaction which<br />causes swelling of the face or throat, serious skin rashes, some<br />disorders affecting blood flow to the eyes, irregular heartbeats,<br />angina and sudden cardiac death.<br />The side effects dizziness and diarrhea have been reported more<br />frequently in men over 75 years of age taking Mygal.<br />If you get any side effects, talk to your doctor or pharmacist.<br />This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Keep out of reach of children.<br />Store below 30&deg;C.<br />Do not use beyond the expiry date or if the product shows any<br />sign of deterioration.<br />Do not throw away any medicines via wastewater or household<br />waste. Ask your pharmacist how to throw away medicines you no<br />longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Mygal 5 mg: Each film coated tablet contains: Tadalafil 5 mg.<br />Mygal 20 mg: Each film coated tablet contains: Tadalafil 20 mg.<br />Excipients: Lactose, croscarmellose sodium, microcrystalline<br />cellulose, hydroxypropyl cellulose, sodium lauryl sulphate,<br />magnesium stearate, HPMC, PEG, titanium dioxide, ferric oxide<br />yellow and simethicone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Mygal 5 mg: Pack 30 Film Coated Tablets.
Mygal 20 mg: Pack 4 Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Manufactured by: Tabuk Pharmaceutical Manufacturing<br />Co.,Madina Road, P.O. Box 3633, Tabuk-Saudi Arabia.<br />For: Cigalah Pharma, Jeddah-Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved at 01/06/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ميجال على المادة الفعالة تادالافيل التي تنتمي إلى مجموعة من الأدوية تعرف<br />. بمثبطات فوسفودايإستيريز نوع 5<br />يستعمل ميجال لعلاج الرجال البالغين الذين يعانون من الحالات التالية:<br />قصور في انتصاب القضيب، حيث لا يستطيع الرجل الحصول، أو المحافظة على انتصاب<br />القضيب المناسب للنشاط الجنسي. أظهر ميجال تحسن كبير في القدرة على الحصول على<br />انتصاب القضيب المناسب للنشاط الجنسي. بعد التحفيز الجنسي يعمل ميجال عن طريق<br />المساعدة في إرخاء الأوعية الدموية في القضيب، مما يسمح بتدفق الدم في القضيب. ينتج عن<br />ذلك تحسن في وظيفة القضيب. لن يساعدك ميجال إن لم تكن تعاني من قصور في انتصاب<br />القضيب.<br />من الضروري معرفة بأن ميجال لعلاج قصور انتصاب القضيب لا يعمل إذا لم يكن هنالك<br />تحفيز جنسي. ستحتاج أنت و الشريك البدء بالمداعبة، كما هو الحال تمام ا إذا لم تكن تتناول<br />دواء لعلاج قصور انتصاب القضيب.<br />يستعمل ميجال 5 ملجم لعلاج الرجال البالغين الذين يعانون من:<br />أعراض بولية ترتبط بحالة شائعة تعرف بتضخم غدة البروستات الحميد، حيث تتضخم غدة<br />البروستات مع التقدم في السن. تتضمن الأعراض صعوبة البدء في التبول، الشعور بأنك لا<br />تستطيع إفراغ المثانة تماما و الشعور في الحاجة للتبول في معظم الأحيان حتى أثناء الليل.<br />يحسن ميجال تدفق الدم، و إرخاء عضلات غدة البروستات و المثانة مما يقلل أعراض تضخم<br />غدة البروستات الحميد.</p><p>أظهر ميجال تحسن لهذه الأعراض البولية بعد 1-2 أسبوع من بدء العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال ميجال<br />- إذا كنت تعاني من الحساسية لتادالافيل أو لأي مكونات أخرى في هذا الدواء.<br />- إذا كنت تتناول أي شكل من النترات العضوية أو مانحات أكسيد النتريك مثل أميل نترات.<br />هذه مجموعة من الأدوية )&quot;النترات&quot;( تستعمل في علاج الذبحة الصدرية )&quot;ألم الصدر&quot;(.<br />أظهر ميجال تأثيره بزيادة مفعول هذه الأدوية. إذا كنت تتناول أي شكل من النترات أو إذا<br />لم تكن متأكداً أخبر طبيبك.<br />- إذا كنت تعاني من مرض قلبي خطير أو عانيت مؤخراً من نوبة قلبية خلال 09 يوم<br />مضى.<br />- إذا عانيت مؤخراً من سكتة دماغية خلال الأشهر الستة الماضية.<br />- إذا كنت تعاني من انخفاض ضغط الدم أو ارتفاع ضغط الدم غير المسيطر عليه.<br />- إذا عانيت في السابق من فقدان للبصر نتيجة لاعتلال عصبي بصري ناتج عن فقر دم<br />موضعي احتباسي أمامي غير شرياني، و هي حالة مرضية توصف كأنها &quot;سكتة للعين&quot;.<br />المحاذير و الاحتياطات<br />استشر طبيبك قبل تناول ميجال.<br />يجب العلم بأن النشاط الجنسي يعرض المرضى الذي يعانون من مرض قلبي للخطر حيث<br />يضع مجهود إضافي على عضلة القلب. إذا كنت تعاني من مشكلة قلبية يجب عليك إخبار<br />الطبيب.<br />لأن تضخم غدة البروستات الحميد و سرطان غدة البروستات قد يكون لديهم نفس<br />الأعراض، سيتأكد الطبيب من عدم إصابتك بسرطان غدة البروستات قبل البدء بميجال<br />لعلاج تضخم غدة البروستات الحميد. لا يعالج ميجال سرطان غدة البروستات.<br />قبل البدء بتناول الأقراص، أخبر طبيبك إذا كنت تعاني من الحالات التالية:<br />- فقر الدم المنجلي )اضطراب في خلايا الدم الحمراء(.<br />- ورم نخاعي متعدد )سرطان نخاع العظم(.<br />- لوكيميا )سرطان خلايا الدم(.<br />- أي تغير في شكل القضيب.<br />- مشكلة خطيرة في الكبد.<br />- مشكلة خطيرة في الكلى.<br />من غير المعروف إذا كان ميجال فعالاً في علاج المرضى الذين خضعوا في السابق لأي<br />مما يلي:<br />- جراحة الحوض.<br />- إزالة لجميع أجزاء غدة البروستات أو لأي جزء منها حيث يتم قطع أعصاب غدة<br />البروستات )استئصال جذري لمنطقة واسعة حول غدة البروستات بما في ذلك الأعصاب<br />في الجزء المستأصل(.<br />إذا حصل لديك نقصان أو فقدان مفاجىء للبصر، توقف عن تناول ميجال و اتصل بالطبيب<br />فوراً.<br />لا يستعمل ميجال للنساء.<br />الأطفال و المراهقون<br />لا يستعمل ميجال للأطفال و المراهقين الأقل من 11 عاما.ً<br />أدوية أخرى و ميجال<br />أخبر طبيبك إذا كنت تتناول، أو تناولت مؤخراً أو من الممكن أن تتناول أي أدوية أخرى.<br />لا تتناول ميجال إذا كنت تتناول النترات.<br />قد تتأثر بعض الأدوية بتناول ميجال أو قد تؤثر تلك الأدوية على جودة عمله. أخبر طبيبك أو<br />الصيدلاني إذا كنت تتناول:<br />- حاصر ألفا )يستعمل لعلاج ارتفاع ضغط الدم أو الأعراض البولية المرتبطة بتضخم غدة<br />البروستات الحميد(.<br />- أدوية أخرى لعلاج ارتفاع ضغط الدم.<br />- مثبط الإنزيم المختزل 5-ألفا )يستعمل لعلاج تضخم غدة البروستات الحميد(.<br />- أدوية مثل أقراص كيتوكونازول )لعلاج الالتهابات الفطرية( و مثبطات البروتياز لعلاج<br />الإيدز أو التهاب فيروس نقص المناعة المكتسبة.<br />- فينوباربيتال، فينيتوين و كاربامازيباين )أدوية مضادة للتشنجات(.<br />- ريفامبيسين، إريثرومايسين، كلاريثرومايسين أو إتراكونازول.<br />- علاجات أخرى لقصور انتصاب القضيب.<br />تناول ميجال مع الطعام والكحول<br />المعلومات عن تأثير الكحول مذكورة في قسم 3. قد يؤثر عصير الجريب فروت على جودة<br />عمل ميجال و يجب تناوله بحذر. اسأل طبيبك عن أي معلومة إضافية.<br />الخصوبة<br />عند علاج الكلاب لوحظ انخفاض في نمو الحيوانات المنوية في الخصيتين. لوحظ هذا<br />الانخفاض عند بعض الرجال. من غير المتوقع أن تؤدي هذه الآثار إلى انخفاض الخصوبة.<br />قيادة المركبات و استخدام الآلات<br />حصل لدى بعض الرجال الذين تناولوا ميجال في الدراسات السريرية شعور بالدوار. تأكد<br />تماما من كيفية تفاعلك مع الأقراص قبل القيادة أو استخدام الآلات.<br />يحتوي ميجال على اللاكتوز:<br />إذا كنت تعاني من عدم القدرة على تحمل بعض أنواع السكريات، قم بالاتصال بالطبيب قبل<br />البدء بتناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول هذا الدواء تماما كما أخبرك الطبيب. تأكد من طبيبك أو الصيدلاني إذا لم تكن<br />متأكداً.<br />أقراص ميجال معدة للاستعمال عن طريق الفم للرجال فقط. ابلع القرص كاملاً مع كأس ماء.<br />من الممكن تناول الأقراص مع أو دون تناول الطعام.<br />لعلاج &nbsp;قصور انتصاب القضيب<br />الجرعة الابتدائية الموصى بها هي 5 ملجم أو 19 ملجم يوميا في نفس الوقت تقريبا من كل<br />يوم. قد يقوم الطبيب بتخفيض الجرعة أو زيادتها، بناءً على كيفية تفاعل جسمك مع ميجال و<br />حالتك الصحية.<br />لا تتناول ميجال أكثر من مرة واحدة يوميا.ً<br />عند تناوله مرة واحدة يوميا،ً سيسمح ميجال لك بالحصول على انتصاب، عند التحفيز<br />الجنسي، في أي وقت من اليوم خلال 24 ساعة. جرعة واحدة يوميا من ميجال قد تكون مفيدة<br />للرجال الذين من المتوقع أن يكون لديهم نشاط جنسي مرتين أو أكثر أسبوعي ا.ً<br />من الضروري معرفة بأن ميجال لا يعمل إذا لم يكن هنالك تحفيز جنسي.<br />ستحتاج أنت و الشريك للبدء بالمداعبة، كما هو الحال إذا لم تكن تتناول دواء لعلاج قصور<br />انتصاب القضيب.<br />لعلاج &nbsp;تضخم غدة البروستات الحميد<br />الجرعة هي قرص واحد 5 ملجم مرة واحدة يوميا في نفس الوقت تقريبا من كل يوم.<br />إذا كنت تعاني من تضخم غدة البروستات الحميد و قصور انتصاب القضيب، ستبقى الجرعة<br />5 ملجم مرة واحدة يوميا.ً<br />لا تتناول ميجال أكثر من مرة واحدة يوميا.ً<br />قد يؤثر شرب الكحول على قدرتك في الحصول على الانتصاب كما يخفض شرب الكحول<br />ضغط الدم بشكل مؤقت. إذا تناولت أو كنت تخطط لتناول ميجال، تجنب الفرط في الشرب<br />)مستوى الكحول في الدم 9.91 % أو أكثر(، حيث من الممكن أن يزيد ذلك من خطورة<br />التعرض للدوار عند الوقوف.<br />إذا تناولت ميجال أكثر مما يجب<br />. قم بالاتصال بالطبيب. قد تحصل لديك آثاراً جانبية مذكورة في قسم 4<br />إذا نسيت تناول جرعة ميجال<br />تناول جرعتك حال تذكرك لكن لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.<br />يجب عدم تناول ميجال أكثر من مرة واحدة يوميا.ً<br />إذا كان لديك أي أسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، قد يسبب هذا الدواء آثاراً جانبية، على الرغم من عدم حدوثها لدى الجميع.<br />هذه الآثار عادة معتدلة إلى متوسطة بطبيعتها.<br />إذا حصل لديك أي من الآثار الجانبية التالية توقف عن استعمال الدواء و اطلب الرعاية<br />الطبية فوراً:<br />- تفاعلات تحسسية بما في ذلك الطفح )التكرار غير شائع(.<br />- آلام الصدر-لا تستعمل النترات لكن اطلب المساعدة الطبية الفورية )التكرار غير شائع(.<br />- انتصاب مطوّل و من الممكن أن يكون مؤلما بعد تناول ميجال )التكرار نادر(.<br />إذا حصل لديك مثل هذا الانتصاب، الذي استمر لفترة أطول من 4 ساعات يجب عليك<br />الاتصال بالطبيب فوراً.<br />- فقدان مفاجىء للبصر )التكرار نادر(.<br />تم تسجيل آثار جانبية أخرى:<br />شائعة )لوحظت عند 1 إلى 19 من كل 199 مريض(<br />- صداع، ألم الظهر، ألم العضلات المستمر، ألم في الذراعين و الساقين، احمرار الوجه،<br />احتقان الأنف، عسر الهضم و الارتداد المعدي المريئي.<br />غير شائعة )لوحظت عند 1 إلى 19 من كل 1999 مريض(<br />- الشعور بالدوار، ألم المعدة، ضبابية الرؤية، ألم العين، زيادة التعرق، صعوبة في التنفس،<br />نزيف قضيبي، ظهور الدم في المني و/أو البول، الشعور بخفقان القلب بشدة، تسارع<br />نبضات القلب، ارتفاع ضغط الدم، انخفاض ضغط الدم، نزيف الأنف و رنين في الأذن.<br />) نادرة )لوحظت عند 1 إلى 19 من كل 19999<br />- الإغماء، نوبات صرع و فقدان للذاكرة، تورم الجفون، احمرار العيون، نقصان أو فقدان<br />مفاجىء للسمع و الشرى )بقع حمراء على سطح الجلد تسبب الحكة(.<br />- تم تسجيل أيضا حدوث نوبة قلبية و سكتة دماغية بشكل نادر عند الرجال الذين تناولوا<br />ميجال. معظم هؤلاء الرجال كان لديهم مشاكل قلبية معروفة قبل البدء بتناول هذا الدواء.<br />- تم تسجيل حدوث نقصان أو فقدان جزئي، مؤقت أو دائم للبصر بشكل نادر في كلا العينتين<br />أو إحداهما.<br />تم تسجيل بعض الآثار الجانبية النادرة الإضافية عند الرجال الذين تناولوا ميجال التي لم<br />تشاهد في التجارب السريرية. هذه الآثار تتضمن:<br />- الشقيقة، تورم الوجه، تفاعل تحسسي خطير الذي يسبب تورم الوجه أو الحلق )البلعوم(،<br />طفح جلدي خطير، بعض الاضطرابات التي تؤثر على تدفق الدم إلى العيون، عدم انتظام<br />نبضات القلب، ذبحة و موت مفاجىء لعضلة القلب.<br />تم تسجيل الآثار الجانبية مثل الشعور بالدوار و الإسهال بتكرار أكبر عند الرجال<br />فوق 55 عاما من العمر و تناولوا ميجال.<br />إذا ازدادت حدة أي من الآثار الجانبية، أو إذا لاحظت أي آثار جانبية غير مذكورة في هذه<br />النشرة، الرجاء أن تخبر طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول الأطفال.<br />يحفظ في درجة حرارة أقل من 39 &deg;م.<br />لا تستعمل الدواء بعد انتهاء مدة صلاحيته أو عند ملاحظة أي علامة تلف فيه.<br />يجب عدم التخلص من أي أدوية عن طريق رميها في المياه العادمة أو النفايات المنزلية.<br />استشر الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه<br />التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ميجال 5 ملجم: يحتوي كل قرص مغلف على: تادالافيل 5 ملجم.<br />ميجال 02 ملجم: يحتوي كل قرص مغلف على: تادالافيل 29 ملجم.<br />السواغات: لاكتوز، كروسكارميلوز الصوديوم، ميكروكريستالين سيليلوز، هيدروكسي<br />بروبيل سيليلوز، صوديوم لوريل سلفات، ستيرات المغنيسيوم، هيدروكسي بروبيل مثيل<br />سيليلوز، بولي إيثيلين جلايكول، ثاني أكسيد التيتانيوم، أكسيد الحديد الأصفر و سيميثيكون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL"><strong>ميجال</strong><strong> 5 </strong><strong>ملجم</strong><strong>: </strong>عبوة تحتوي على 10، 30 قرصا مغلفا.</p><p style="text-align:right" dir="RTL"><strong>ميجال</strong><strong> </strong><strong>20</strong><strong> </strong><strong>ملجم</strong><strong>: </strong>عبوة تحتوي على 1، 4، 8 قرصا مغلفا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إنتاج &nbsp;:شركة تبوك للصناعات الدوائية،<br />طريق المدينة، ص.ب 3633 ، تبوك-المملكة العربية السعودية.<br />لصالح :شركة سقالة فارما ,جدة-المملكة العربية السعودية..</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ 01/06/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mygal 20 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains: Tadalafil 20 mg For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet. Mygal 20 mg Tablet : Yellow colored, almond shaped film coated tablets engraved with ‘VZ’ on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Treatment of erectile dysfunction in adult males. In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Posology Erectile dysfunction in adult Men In general, the recommended dose is 10mg taken prior to anticipated sexual activity and with or without food. In those patients in whom tadalafil 10mg does not produce an adequate effect, 20mg might be tried. It may be taken at least 30 minutes prior to sexual activity. The maximum dose frequency is once per day. Tadalafil 10mg and 20mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous daily use. In patients who anticipate a frequent use of Mygal (i.e., at least twice weekly) a once daily regimen with the lowest doses of Mygal might be considered suitable, based on patient choice and the physician&#39;s judgement. In these patients, the recommended dose is 5mg taken once a day at approximately the same time of day. The dose may be decreased to 2.5mg once a day based on individual tolerability. The appropriateness of continued use of the daily regimen should be reassessed periodically.<br />Benign prostatic hyperplasia in adult men The recommended dose is 5 mg, taken at approximately the same time every day with or without food. For adult men being treated for both benign prostatic hyperplasia and erectile dysfunction the recommended dose is also 5 mg taken at approximately the same time every day. Patients who are unable to tolerate tadalafil 5 mg for the treatment of benign prostatic hyperplasia should consider an alternative therapy as the efficacy of tadalafil 2.5mg for the treatment of benign prostatic hyperplasia has not been demonstrated. Special Populations Elderly Men Dose adjustments are not required in elderly patients. Men with Renal Impairment Dose adjustments are not required in patients with mild to moderate renal impairment. For patients with severe renal impairment, 10mg is the maximum recommended dose for on-demand treatment. Once-a-day dosing or 5 mg tadalafil both for the treatment of erectile dysfunction or benign prostatic hyperplasia is not recommended in patients with severe renal impairment. (See sections 4.4 and 5.2.) Men with Hepatic Impairment For the treatment of erectile dysfunction using on-demand Mygal the recommended dose of Mygal is 10mg taken prior to anticipated sexual activity and with or without food. There is limited clinical data on the safety of Mygal in patients with severe hepatic impairment (Child-Pugh class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10mg of tadalafil to patients with hepatic impairment. Once-a-day dosing of Mygal both for the treatment of erectile dysfunction and benign prostatic hyperplasia has not been evaluated in patients with hepatic impairment; therefore if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. (See sections 4.4 and 5.2.) Men with Diabetes Dose adjustments are not required in diabetic patients. Paediatric population There is no relevant use of Mygal in the pediatrics population with regard to the treatment of erectile dysfunction. Method of administration Mygal is available as 5 and 20 mg film-coated tablets for oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of MYGAL to patients who are using any form of organic nitrate is contraindicated. (See section 4.5.) Mygal, must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease. The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated: • Patients with myocardial infarction within the last 90 days. • Patients with unstable angina or angina occurring during sexual intercourse. • Patients with New York Heart Association class 2 or greater heart failure in the last 6 months. • Patients with uncontrolled arrhythmias, hypotension (<90/50mmHg), or uncontrolled hypertension. • Patients with a stroke within the last 6 months. Mygal is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Before treatment with Mygal, A medical history and physical examination should be undertaken to diagnose erectile dysfunction or benign prostatic hyperplasia and determine potential underlying causes, before pharmacological treatment is considered. Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1), and as such potentiates the hypotensive effect of nitrates (see section 4.3). Prior to initiating treatment with tadalafil for benign prostatic hyperplasia patients should be examined to rule out the presence of carcinoma of the prostate and carefully assessed for cardiovascular conditions (see section 4.3). The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following an appropriate medical assessment. It is not known if Mygal is effective in patients who have undergone pelvic surgery or radical non-nerve-sparing prostatectomy. Cardiovascular Serious cardiovascular events, including myocardial infarction, sudden cardiac death, unstable angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest pain, palpitations and tachycardia, have been reported either post marketing and/or in clinical trials. Most of the patients in whom these events have been reported had pre-existing cardiovascular risk factors. However, it is not possible to definitively determine whether these events are related directly to these risk factors, to Mygal, to sexual activity, or to a combination of these or other factors. Tadalafil (5mg) - In patients receiving concomitant antihypertensive medicinal products, tadalafil may induce a blood pressure decrease. When initiating daily treatment with tadalafil, appropriate clinical considerations should be given to a possible dose adjustment of the antihypertensive therapy. In patients who are taking alpha1 blockers, concomitant administration of Mygal may lead to symptomatic hypotension in some patients (see section 4.5). The combination of tadalafil and doxazosin is not recommended. Vision Visual defects and cases of NAION have been reported in connection with the intake of Mygal and other PDE5 inhibitors. The patient should be advised that in case of sudden visual defect, he should stop taking Mygal and consult a physician immediately (see section 4.3). Renal and hepatic impairment Due to increased tadalafil exposure (AUC), limited clinical experience and the lack of ability to influence clearance by dialysis, once-a-day dosing of Mygal is not recommended in patients with severe renal impairment. There is limited clinical data on the safety of single-dose administration of Mygal in patients with severe hepatic insufficiency (Child-Pugh class C). Once-a-day administration either for the treatment of erectile dysfunction or benign prostatic hyperplasia has not been evaluated in patients with hepatic insufficiency. If Mygal is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. Priapism and anatomical deformation of the penis Patients who experience erections lasting 4 hours or more should be instructed to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. Mygal, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie&#39;s disease) or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma, or leukaemia). Use with CYP3A4 inhibitors Caution should be exercised when prescribing Mygal to patients using potent CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased tadalafil exposure (AUC) has been observed if the medicinal products are combined (see section 4.5). Mygal and other treatments for erectile dysfunction The safety and efficacy of combinations of Mygal and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied. The patients should be informed not to take Mygal in such combinations. Lactose Mygal contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Interaction studies were conducted with 10mg and/or 20mg tadalafil, as indicated below. With regard to those interaction studies where only the 10mg tadalafil dose was used, clinically relevant interactions at higher doses cannot be completely ruled out. Effects of Other Substances on Tadalafil Cytochrome P450 inhibitors Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole (200mg daily), increased tadalafil (10mg) exposure (AUC) 2-fold and Cmax by 15%, relative to the AUC and Cmax values for tadalafil alone. Ketoconazole (400mg daily) increased tadalafil (20mg) exposure (AUC) 4-fold and Cmax by 22%. Ritonavir, a protease inhibitor (200mg twice daily), which is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20mg) exposure (AUC) 2-fold with no change in Cmax. Although specific interactions have not been studied, other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin, clarithromycin, itraconazole, and grapefruit juice, should be co-administered with caution, as they would be expected to increase plasma concentrations of tadalafil (see section 4.4). Consequently, the incidence of the adverse reactions listed in section 4.8 might be increased. Transporters The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not known. Therefore, there is the potential of drug interactions mediated by inhibition of transporters. Cytochrome P450 inducers A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for tadalafil alone (10mg). This reduced exposure can be anticipated to decrease the efficacy of tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4, such as phenobarbital, phenytoin, and carbamazepine, may also decrease plasma concentrations of tadalafil. Effects of Tadalafil on Other Medicinal Products Nitrates In clinical studies, tadalafil (5mg, 10mg and 20mg) was shown to augment the hypotensive effects of nitrates. Therefore, administration of Mygal to patients who are using any form of organic nitrate is contraindicated (see section 4.3). Based on the results of a clinical study in which 150 subjects received daily doses of tadalafil 20mg for 7 days and 0.4mg sublingual nitroglycerin at various times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of Mygal ( 20 mg), where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of Mygal before nitrate administration is considered. In such circumstances, nitrates should only be administered under close medical supervision with appropriate haemodynamic monitoring. Anti-hypertensives (including calcium channel blockers) The co-administration of doxazosin (4 and 8mg daily) and tadalafil (5mg daily dose and 20mg as a single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner. This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore, this combination is not recommended (see section 4.4). In interaction studies performed in a limited number of healthy volunteers, these effects were not reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at minimal dosage and progressively adjusted. In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal products were studied, including calcium-channel blockers (amlodipine), angiotensin converting enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics (bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in combination with thiazides, calcium-channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil (10mg, except for studies with angiotensin II receptor blockers and amlodipine in which a 20mg dose was applied) had no clinically significant interaction with any of these classes. In another clinical pharmacology study, tadalafil (20mg) was studied in combination with up to 4 classes of antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure changes appeared to relate to the degree of blood pressure control. In this regard, study subjects whose blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy subjects. In study subjects whose blood pressure was not controlled, the reduction was greater, although this reduction was not associated with hypotensive symptoms in the majority of subjects. In patients receiving concomitant antihypertensive medicinal products, tadalafil 20mg may induce a blood pressure decrease, which (with the exception of alpha-blockers - see above) is, in general, minor and not likely to be clinically relevant. Analysis of Phase 3 clinical trial data showed no difference in adverse events in patients taking tadalafil with or without antihypertensive medicinal products. However, appropriate clinical advice should be given to patients regarding a possible decrease in blood pressure when they are treated with antihypertensive medicinal products. 5- alpha reductase inhibitors In a clinical trial that compared tadalafil 5 mg coadministered with finasteride 5 mg to placebo plus finasteride 5 mg in the relief of BPH symptoms, no new adverse reactions were identified. However, as a formal drug-drug interaction study evaluating the effects of tadalafil and 5-alpha reductase inhibitors (5-ARIs) has not been performed, caution should be exercised when tadalafil is co-administered with 5-ARIs.<br />CYP1A2 substrates (e.g. theophylline) When tadalafil 10mg was administered with theophylline (a non-selective phosphodiesterase inhibitor) in a clinical pharmacology study, there was no pharmacokinetic interaction. The only pharmacodynamic effect was a small (3.5 bpm) increase in heart rate. Although this effect is minor and was of no clinical significance in this study, it should be considered when co-administering these medicinal products. Ethinylestradiol and terbutaline Tadalafil has been demonstrated to produce an increase in the oral bioavailability of ethinylestradiol; a similar increase may be expected with oral administration of terbutaline, although the clinical consequence of this is uncertain. Alcohol Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by co-administration with tadalafil (10mg or 20mg). In addition, no changes in tadalafil concentrations were seen 3 hours after co-administration with alcohol. Alcohol was administered in a manner to maximise the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol). Tadalafil (20mg) did not augment the mean blood pressure decrease produced by alcohol (0.7g/kg or approximately 180ml of 40% alcohol [vodka] in an 80 kg male) but, in some subjects, postural dizziness and orthostatic hypotension were observed. When tadalafil was administered with lower doses of alcohol (0.6g/kg), hypotension was not observed and dizziness occurred with similar frequency to alcohol alone. The effect of alcohol on cognitive function was not augmented by tadalafil (10mg). Cytochrome P450 metabolised medicinal products Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of medicinal products metabolised by CYP450 isoforms. Studies have confirmed that tadalafil does not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and CYP2C19. CYP2C9 substrates (e.g. R-warfarin) Tadalafil (10mg and 20mg) had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by warfarin. Aspirin Tadalafil (10mg and 20mg) did not potentiate the increase in bleeding time caused by acetylsalicylic acid. Antidiabetic medicinal products Specific interaction studies with antidiabetic medicinal products were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Mygal is not indicated for use by women. Pregnancy Pregnancy category B<br />There are limited data from the use of tadalafil in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Mygal during pregnancy. Breastfeeding Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil in milk. A risk to the suckling child cannot be excluded. Mygal should not be used during breast feeding. Fertility Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical studies suggest that this effect is unlikely in humans, although a decrease in sperm concentration was seen in some men (see sections 5.1 and 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Mygal has negligible influence on the ability to drive or use machines. Although the frequency of reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should be aware of how they react to Mygal before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Summary of the safety profile The most commonly reported adverse reactions in patients taking Mygal for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of Mygal. The adverse reactions reported were transient, and generally mild or moderate. The majority of headaches reported with Mygal once-a-day dosing are experienced within the first 10 to 30 days of starting treatment Tabulated summary of adverse reactions The table below lists the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials (comprising a total of 7116 patients on Mygal and 3718 patients on placebo) for on-demand and once-a-day treatment of erectile dysfunction and the once-a-day treatment of benign prostatic hyperplasia. Frequency convention: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to&lt;1/1000), Very Rare (&lt;1/10,000) and Not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:23.1pt; vertical-align:top; width:122.85pt"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><strong>Very common</strong></p></td><td style="height:23.1pt; vertical-align:top; width:123.0pt"><p style="margin-left:2.85pt; margin-right:0cm; text-align:left"><strong>Common</strong></p></td><td style="height:23.1pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:0cm; text-align:left"><strong>Uncommon</strong></p></td><td style="height:23.1pt; vertical-align:top; width:122.85pt"><p style="margin-left:2.8pt; margin-right:0cm; text-align:left"><strong>Rare</strong></p></td></tr><tr><td style="height:23.45pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Immune system disorders</em></p></td></tr><tr><td style="height:37.35pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:37.35pt; vertical-align:top; width:123.0pt"><p style="text-align:left">&nbsp;</p></td><td style="height:37.35pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:37.65pt; text-align:left">Hypersensitivity reactions</p></td><td style="height:37.35pt; vertical-align:top; width:122.85pt"><p style="margin-left:2.8pt; margin-right:0cm; text-align:left">Angioedema<sup>2</sup></p></td></tr><tr><td style="height:23.55pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Nervous system disorders</em></p></td></tr><tr><td style="height:92.6pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:92.6pt; vertical-align:top; width:123.0pt"><p style="margin-left:2.85pt; margin-right:0cm; text-align:left">Headache</p></td><td style="height:92.6pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:0cm; text-align:left">Dizziness</p></td><td style="height:92.6pt; vertical-align:top; width:122.85pt"><p style="margin-left:2.8pt; margin-right:11.3pt; text-align:left">Stroke<sup>1</sup> (including haemorrhagic events), Syncope, Transient ischaemic attacks<sup>1</sup>, Migraine<sup>2</sup>, Seizures, Transient amnesia</p></td></tr><tr><td style="height:23.45pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Eye disorders</em></p></td></tr><tr><td style="height:134.0pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:134.0pt; vertical-align:top; width:123.0pt"><p style="text-align:left">&nbsp;</p></td><td style="height:134.0pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:4.55pt; text-align:left">Blurred vision, Sensations described as eye pain</p></td><td style="height:134.0pt; vertical-align:top; width:122.85pt"><p style="margin-left:2.8pt; margin-right:6.5pt; text-align:left">Visual field defect, Swelling of eyelids, Conjunctival hyperaemia, Non- arteritic anterior ischaemic optic neuropathy (NAION)<sup>2</sup>, Retinal vascular occlusion<sup>2</sup></p></td></tr><tr><td style="height:23.55pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="height:23.55pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:23.55pt; vertical-align:top; width:123.0pt"><p style="text-align:left">&nbsp;</p></td><td style="height:23.55pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:0cm; text-align:left">Tinnitus</p></td><td style="height:23.55pt; vertical-align:top; width:122.85pt"><p style="margin-left:2.8pt; margin-right:0cm; text-align:left">Sudden hearing loss</p></td></tr><tr><td style="height:23.45pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Cardiac disorders<sup>1</sup></em></p></td></tr><tr><td style="height:64.95pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:64.95pt; vertical-align:top; width:123.0pt"><p style="text-align:left">&nbsp;</p></td><td style="height:64.95pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:55.25pt; text-align:left">Tachycardia, Palpitations</p></td><td style="height:64.95pt; vertical-align:top; width:122.85pt"><p style="margin-left:2.8pt; margin-right:9.75pt; text-align:left">Myocardial infarction, Unstable angina pectoris<sup>3</sup>, Ventricular arrhythmia<sup>3</sup></p></td></tr><tr><td style="height:23.6pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Vascular disorders</em></p></td></tr><tr><td style="height:37.25pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:37.25pt; vertical-align:top; width:123.0pt"><p style="margin-left:2.85pt; margin-right:0cm; text-align:left">Flushing</p></td><td style="height:37.25pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:48.6pt; text-align:left">Hypotension<sup>3</sup>, Hypertension</p></td><td style="height:37.25pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="height:23.55pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="height:23.55pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:23.55pt; vertical-align:top; width:123.0pt"><p style="margin-left:2.85pt; margin-right:0cm; text-align:left">Nasal congestion</p></td><td style="height:23.55pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:0cm; text-align:left">Dyspnoea, Epistaxis</p></td><td style="height:23.55pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="height:23.55pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="height:37.25pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:37.25pt; vertical-align:top; width:123.0pt"><p style="margin-left:2.85pt; margin-right:25.25pt; text-align:left">Dyspepsia, Gastro- oesophageal reflux</p></td><td style="height:37.25pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:0cm; text-align:left">Abdominal pain</p></td><td style="height:37.25pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="height:23.1pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Skin and subcutaneous tissue disorders</em></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:50.75pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:50.75pt; vertical-align:top; width:123.0pt"><p style="text-align:left">&nbsp;</p></td><td style="height:50.75pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:16.6pt; text-align:left">Rash, Hyperhydrosis (sweating)</p></td><td style="height:50.75pt; vertical-align:top; width:122.85pt"><p style="margin-left:2.8pt; margin-right:9.45pt; text-align:left">Urticaria, Stevens- Johnson syndrome<sup>2</sup>, Exfoliative dermatitis<sup>2</sup></p></td></tr><tr><td style="height:23.45pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Renal and urinary disorders</em></p></td></tr><tr><td style="height:23.55pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:23.55pt; vertical-align:top; width:123.0pt"><p style="text-align:left">&nbsp;</p></td><td style="height:23.55pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:0cm; text-align:left">Haematuria</p></td><td style="height:23.55pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="height:23.55pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Musculoskeletal, connective tissue and bone disorders</em></p></td></tr><tr><td style="height:37.35pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:37.35pt; vertical-align:top; width:123.0pt"><p style="margin-left:2.85pt; margin-right:20.8pt; text-align:left">Back pain, Myalgia, Pain in extremity</p></td><td style="height:37.35pt; vertical-align:top; width:123.0pt"><p style="text-align:left">&nbsp;</p></td><td style="height:37.35pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="height:23.45pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="height:37.35pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:37.35pt; vertical-align:top; width:123.0pt"><p style="text-align:left">&nbsp;</p></td><td style="height:37.35pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:18.7pt; text-align:left">Penile haemorrhage, Haematospermia</p></td><td style="height:37.35pt; vertical-align:top; width:122.85pt"><p style="margin-left:2.8pt; margin-right:19.2pt; text-align:left">Prolonged erections, Priapism<sup>2</sup></p></td></tr><tr><td style="height:23.55pt; vertical-align:top; width:491.7pt" colspan="4"><p style="margin-left:3.05pt; margin-right:0cm; text-align:left"><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="height:36.9pt; vertical-align:top; width:122.85pt"><p style="text-align:left">&nbsp;</p></td><td style="height:36.9pt; vertical-align:top; width:123.0pt"><p style="text-align:left">&nbsp;</p></td><td style="height:36.9pt; vertical-align:top; width:123.0pt"><p style="margin-left:3.15pt; margin-right:0cm; text-align:left">Chest pain<sup>1</sup></p></td><td style="height:36.9pt; vertical-align:top; width:122.85pt"><p style="margin-left:2.8pt; margin-right:5.4pt; text-align:left">Facial oedema<sup>2</sup>, Sudden cardiac death<sup>1,2</sup></p></td></tr></tbody></table><p style="text-align:left">1 Most of the patients had pre-existing cardiovascular risk factors (see section 4.4).<br />2 Postmarketing surveillance reported adverse reactions not observed in placebo-controlled clinical trials.<br />3 More commonly reported when tadalafil is given to patients who are already taking antihypertensive<br />medicinal products.<br />Description of selected adverse reactions<br />A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been reported in<br />patients treated with tadalafil once a day as compared with placebo. Most of these ECG abnormalities were<br />not associated with adverse reactions.<br />Other special populations<br />Data in patients over 65 years of age receiving tadalafil in clinical trials, either for the treatment of erectile<br />dysfunction or the treatment of benign prostatic hyperplasia, are limited. In clinical trials with tadalafil 5mg<br />taken once a day for the treatment of benign prostatic hyperplasia, dizziness and diarrhoea were reported<br />more frequently in patients over 75 years of age.</p><p style="text-align:left">To report any side effects<br />National Pharmacovigilance &amp; Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at: +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Single doses of up to 500mg have been given to healthy subjects, and multiple daily doses up to 100mg have been given to patients. Adverse events were similar to those seen at lower doses. In cases of overdose, standard supportive measures should be adopted, as required. Haemodialysis contributes negligibly to tadalafil elimination.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction. ATC code: G04BE08. Mechanism of action Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Tadalafil has no effect in the treatment of erectile dysfunction in the absence of sexual stimulation. The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The resulting vascular relaxation increases blood perfusion which may be the mechanism by which symptoms of benign prostatic hyperplasia are reduced. These vascular effects may be complemented by inhibition of bladder afferent nerve activity and smooth muscle relaxation of the prostate and bladder. Pharmacodynamic effects Studies in vitro have shown that tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal muscle, platelets, kidney, lung, and cerebellum. The effect of tadalafil is more potent on PDE5 than on other phosphodiesterases. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE1, PDE2, and PDE4, enzymes which are found in the heart, brain, blood vessels, liver, and other organs. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels. This selectivity for PDE5 over PDE3 is important because PDE3 is an enzyme involved in cardiac contractility. Additionally, tadalafil is approximately 700-fold more potent for PDE5 than for PDE6, an enzyme which is found in the retina and is responsible for phototransduction. Tadalafil is also &gt;10,000-fold more potent for PDE5 than for PDE7 through PDE10. Clinical efficacy and safety Tadalafil administered to healthy subjects produced no significant difference compared to placebo in supine systolic and diastolic blood pressure (mean maximal decrease of 1.6/0.8mmHg, respectively), in standing systolic and diastolic blood pressure (mean maximal decrease of 0.2/4.6mmHg, respectively), and no significant change in heart rate. In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is consistent with the low affinity of tadalafil for PDE6 compared to PDE5. Across all clinical studies, reports of changes in colour vision were rare (&lt;0.1%). Three studies were conducted in men to assess the potential effect on spermatogenesis of Tadalafil 10mg (one 6-month study) and 20mg (one 6-month and one 9-month study) administered daily. In two of these studies decreases were observed in sperm count and concentration related to tadalafil treatment of unlikely clinical relevance. These effects were not associated with changes in other parameters, such as motility, morphology, and FSH. Erectile dysfunction Three clinical studies were conducted in 1054 patients in an at-home setting to define the period of responsiveness to Mygal. Tadalafil demonstrated statistically significant improvement in erectile function and the ability to have successful sexual intercourse up to 36 hours following dosing, as well as patients&#39; ability to attain and maintain erections for successful intercourse compared to placebo as early as 16 minutes following dosing. In a 12-week study performed in 186 patients (142 tadalafil, 44 placebo) with erectile dysfunction secondary to spinal cord injury, tadalafil significantly improved the erectile function leading to a mean per-subject proportion of successful attempts in patients treated with tadalafil 10 or 20 mg (flexible-dose, on demand) of 48% as compared to 17% with placebo. Tadalafil at doses of 2 to 100mg has been evaluated in 16 clinical studies involving 3250 patients, including patients with erectile dysfunction of various severities (mild, moderate, severe), etiologies, ages (range 21-86 years), and ethnicities. Most patients reported erectile dysfunction of at least 1 year in duration. In the primary efficacy studies of general populations, 81% of patients reported that Mygal improved their erections as compared to 35% with placebo. Also, patients with erectile dysfunction in all severity categories reported improved erections whilst taking Mygal (86%, 83%, and 72% for mild, moderate, and severe, respectively, as compared to 45%, 42%, and 19% with placebo). In the primary efficacy studies, 75% of intercourse attempts were successful in Mygal-treated patients as compared to 32% with placebo. For once-a-day evaluation of tadalafil at doses of 5, and 10 mg 3 clinical studies were initially conducted involving 853 patients of various ages (range 21-82 years) and ethnicities, with erectile dysfunction of various severities (mild, moderate, severe) and etiologies. In the two primary efficacy studies of general populations, the mean per-subject proportion of successful intercourse attempts were 57 and 67% on Mygal 5mg, 50% on Mygal 2.5mg as compared to 31 and 37% with placebo. In the study in patients with erectile dysfunction secondary to diabetes, the mean per-subject proportion of successful attempts were 41 and 46% on Mygal 5mg and 2.5mg, respectively, as compared to 28% with placebo. Most patients in these three studies were responders to previous on-demand treatment with PDE5 inhibitors. In a subsequent study, 217 patients who were treatment-naive to PDE5 inhibitors were randomised to Mygal 5mg once a day vs. placebo. The mean per-subject proportion of successful sexual intercourse attempts was 68% for Mygal patients compared to 52% for patients on placebo. Benign prostatic hyperplasia Mygal was studied in 4 clinical studies of 12 weeks duration enrolling over 1500 patients with signs and symptoms of benign prostatic hyperplasia. The improvement in the total international prostate symptom score with Mygal 5mg in the four studies were -4.8, -5.6, -6.1 and -6.3 compared to -2.2, -3.6, -3.8 and -4.2 with placebo. The improvements in total international prostate symptom score occurred as early as 1 week.<br />In one of the studies, which also included tamsulosin 0.4 mg as an active comparator, the improvement in total international prostate symptom score with Mygal 5mg, tamsulosin and placebo were -6.3, -5.7 and -4.2 respectively. One of these studies assessed improvements in erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in patients with both conditions. The improvements in the erectile function domain of the international index of erectile function and the total international prostate symptom score in this study were 6.5 and -6.1 with Mygal 5 mg compared to 1.8 and -3.8 with placebo, respectively. The mean per-subject proportion of successful sexual intercourse attempts was 71.9% with Mygal 5 mg compared to 48.3% with placebo. The maintenance of the effect was evaluated in an open-label extension to one of the studies, which showed that the improvement in total international prostate symptom score seen at 12 weeks was maintained for up to 1 additional year of treatment with Mygal 5mg. Paediatric population The European Medicines Agency has waived the obligation to submit the results of studies in all subsets of the paediatric population in the treatment of the erectile dysfunction. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Absorption Tadalafil is readily absorbed after oral administration and the mean maximum observed plasma concentration (Cmax) is achieved at a median time of 2 hours after dosing. Absolute bioavailability of tadalafil following oral dosing has not been determined. The rate and extent of absorption of tadalafil are not influenced by food, thus Mygal may be taken with or without food. The time of dosing (morning versus evening) had no clinically relevant effects on the rate and extent of absorption. Distribution The mean volume of distribution is approximately 63 litres, indicating that tadalafil is distributed into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins. Protein binding is not affected by impaired renal function. Less than 0.0005% of the administered dose appeared in the semen of healthy subjects. Biotransformation Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The major circulating metabolite is the methylcatechol glucuronide. This metabolite is at least 13,000-fold less potent than tadalafil for PDE5. Consequently, it is not expected to be clinically active at observed metabolite concentrations. Elimination Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose). Linearity/Non-Linearity Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over a dose range of 2.5mg to 20mg, exposure (AUC) increases proportionally with dose. Steady-state plasma concentrations are attained within 5 days of once daily dosing. Pharmacokinetics determined with a population approach in patients with erectile dysfunction are similar to pharmacokinetics in subjects without erectile dysfunction. Special Populations Elderly Healthy elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in 25% higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of age is not clinically significant and does not warrant a dose adjustment. Renal Insufficiency In clinical pharmacology studies using single dose tadalafil (5mg-20mg), tadalafil exposure (AUC) approximately doubled in subjects with mild (creatinine clearance 51 to 80ml/min) or moderate (creatinine clearance 31 to 50ml/min) renal impairment and in subjects with end-stage renal disease on dialysis. In haemodialysis patients, Cmax was 41% higher than that observed in healthy subjects. Haemodialysis contributes negligibly to tadalafil elimination. Hepatic Insufficiency Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-Pugh class A and B) is comparable to exposure in healthy subjects when a dose of 10mg is administered. There is limited clinical data on the safety of Mygal in patients with severe hepatic insufficiency (Child-Pugh class C). If Mygal is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10mg of tadalafil to patients with hepatic impairment. There are no available data about the administration of once-a-day dosing of tadalafil to patients with hepatic impairment. If Mygal is prescribed once-a-day, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. Patients with Diabetes Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC value for healthy subjects. This difference in exposure does not warrant a dose adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction. There was no evidence of teratogenicity, embryotoxicity, or foetotoxicity in rats or mice that received up to 1000mg/kg/day tadalafil. In a rat prenatal and postnatal development study, the no observed effect dose was 30mg/kg/day. In the pregnant rat the AUC for calculated free drug at this dose was approximately 18-times the human AUC at a 20mg dose. There was no impairment of fertility in male and female rats. In dogs given tadalafil daily for 6 to 12 months at doses of 25mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7-18.6] than seen in humans given a single 20mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs. See also section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Lactose Monohydrate Croscarmellose Sodium Low substituted Hydroxypropyl Cellulose Sodium Lauryl Sulfate Microcrystalline Cellulose Magnesium stearate Opadry OY 7300 Ferric Oxide Yellow Simethicone Emulsion</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">One PVC/Aclar Blister of 4 tablets; packed in a printed carton with a folded leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by Tabuk Pharmaceutical Manufacturing Co.
Astra industrial group building.
Salah Aldain Road, King abdulaziz Area.
Riyadh, Saudi Arabia
P.O.Box 28170 Riyadh 11437

Marketed by Cigalah Pharma – Jeddah.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26 March 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>